Asymmetrical dendritic compound of the Formula (I) as described herein can contain multiple functional moieties as represented by R1 and R2 in Formula (I). In various embodiments, the functional moieties include N-Boc, a targeting ligand, a drug, and/or an imaging agent. A number of such functionalized asymmetrical dendritic compounds can be used for various therapies, including cancer treatment.